Protein / target
Ephrin type-A receptor 8
Protein at a glance
Biological role
Transmembrane-ephrin receptor
Strongest disease association
Neuroendocrine Tumors
Therapeutic position
Established drug target
Research activity
Emerging research
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
View complete UniProt function annotationHide complete annotation
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. The GPI-anchored ephrin-A EFNA2, EFNA3, and EFNA5 are able to activate EPHA8 through phosphorylation. With EFNA5 may regulate integrin-mediated cell adhesion and migration on fibronectin substrate but also neurite outgrowth. During development of the nervous system also plays a role in axon guidance. Downstream effectors of the EPHA8 signaling pathway include FYN which promotes cell adhesion upon activation by EPHA8 and the MAP kinases in the stimulation of neurite outgrowth (By similarity)
Subcellular location
Domains and Gene Ontology detail (24)Hide
Domains & features
Gene Ontology
- Cdendrite
- Cearly endosome membrane
- Cneuron projection
- Cplasma membrane
- FATP binding
- Fephrin receptor activity
- FGPI-linked ephrin receptor activity
- Fgrowth factor binding
- Ftransmembrane-ephrin receptor activity
- Paxon guidance
- Pcell adhesion
- Pephrin receptor signaling pathway
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Receptor tyrosine kinase signalling
- ·Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands…
Cell migration
- ·substrate-dependent cell migration
Cell adhesion
- ·Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands…
- ·cell adhesion
- ·regulation of cell adhesion
- ·regulation of cell adhesion mediated by integrin
Immune signalling
- ·Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands…
- ·substrate-dependent cell migration
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene EPHA8
Gene-level evidence surfaced through the gene EPHA8 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (4)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
1 compounds recorded · 1 approved
View all recorded compounds (1)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
View underlying tractability evidence (8)Hide
Raw Open Targets tractability assessment buckets, by modality.
Research activity
Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.
Most cited
Recent
Europe PMC papers linked directly to this protein.